Routine Gene Testing Advised To Guide Colorectal Cancer Treatment
This article was originally published in The Gray Sheet
Executive Summary
The American Society of Clinical Oncology Jan. 13 recommended that physicians treating metastatic colorectal cancer patients who are candidates for drugs such as ImClone's Erbitux (cetuximab) or Amgen's Vectibix (panitumumab) first be tested for KRASgene mutations